anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, therapy, pharmacology. SUBSTANCE: invention relates to method of modulation and/or reproduction of effects of endogenous production of cytokines and hemopoietic factors and/or induction of apoptosis mechanisms. Method involves administration of effective amount of oxidized glutathione or its pharmaceutically acceptable derivative in mammalian organism needing with stimulation of cytokines or hemopoietic factors for time that is sufficient for modulation of endogenous production of cytokines and hemopoietic factors to obtain therapeutic effect. Indicated oxidized glutathione and/or its pharmaceutically acceptable salts and/or pharmaceutically acceptable derivatives are administrated by parenteral or topical route. Oxidized glutathione and/or its pharmaceutically acceptable salts and/or pharmaceutically acceptable derivatives are administrated in combination with prolongator of indicated oxidized glutathione half-life and/or its pharmaceutically acceptable salts and/or its pharmaceutically acceptable derivatives half-life. EFFECT: broadened spectrum of agents for regulation of production of cytokines and hemopoietic factors. 56 cl, 7 dwg, 48 tbl, 27 ex
The present invention is directed to certain multiprotein compounds and methods for using such compounds in the treatment of psoriasis, arthritis, erythropoietic protoporphyria, and scar tissue and wounds. These multiprotein compounds include beta-lactoglobulin, alpha-lactalbumin, and bacitracin. The beta-lactoglobulin proteins are linked to alpha-lactalbumin proteins by a plurality of organic linkages formed by reacting various alcohols, e.g., noncyclic alcohols, steroid alcohols, triterpenoid alcohols, and thioglycerol therewith. The alpha-lactalbumin proteins are linked to the bacitracin proteins by a plurality of organic linkages formed by reacting with fatty acids therewith. A selenium ion may be bonded to each bacitracin protein molecule of the multiprotein compounds. Additionally, pairs of bacitracin molecules may be linked by zinc ions or other cations, to form a salt with the bacitracin.
Noncommunicable diseases (NCD), such as obesity, diabetes, and cardiovascular disease, are defining healthcare challenges of the 21st century. Medical infrastructure, which for decades sought to reduce the incidence and severity of communicable diseases, has proven insufficient in meeting the intensive, long-term monitoring needs of many NCD disease patient groups. In addition, existing portable devices with rigid electronics are still limited in clinical use due to unreliable data, limited functionality, and lack of continuous measurement ability. Here, a wearable system for at-home cardiovascular monitoring of postpartum women-a group with urgently unmet NCD needs in the United States-using a cloud-integrated soft sternal device with conformal nanomembrane sensors is introduced. A supporting mobile application provides device data to a custom cloud architecture for real-time waveform analytics, including medical device-grade blood pressure prediction via deep learning, and shares the results with both patient and clinician to complete a robust and highly scalable remote monitoring ecosystem. Validated in a month-long clinical study with 20 postpartum Black women, the system demonstrates its ability to remotely monitor existing disease progression, stratify patient risk, and augment clinical decision-making by informing interventions for groups whose healthcare needs otherwise remain unmet in standard clinical practice.
PCT No. PCT/DK95/00305 Sec. 371 Date Jan. 3, 1995 Sec. 102(e) Date Jan. 3, 1995 PCT Filed Sep. 23, 1993 PCT Pub. No. WO94/07851 PCT Pub. Date Apr. 14, 1994A compound of formula I    <IMAGE>  I  wherein R stands for a straight or branched, saturated or unsaturated alkyl group containing from 4 to 12 carbon atoms optionally substituted with a hydroxy group, and possibly containing a ring structure, and in which at least one of the carbon atoms not bearing hydroxyl group is substituted with one or more halogen atoms or an azido group; and prodrugs of I in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo, in pure form or in mixtures. The compounds show antiinflammatory and immunomodulating effects as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells. The compounds are prepared by oxidizing 1(S),3(R)-bis-(tert-butyldimethylsilyloxy)-20(S)formyl-9,10-seco-pregna-5(E),7(E),10(19)-triene, reducing the resulting product; alkylating the reduction product and then subjecting the alkylated product to triplet-sensitized photoisomerization.
A composition and method for treatment for bowel disorders is described. The composition consists of three parts. The first part is a highly purified, insoluble, chemically unmodified fiber from plants which is mixed with an aqueous solution such as water. The second part of the composition is a commercially available probiotic preparation. These commercially probiotic preparations contain large numbers of viable microorganisms of either  Lactobacillus  sp.,  Bifidobacter  sp.,  Streptococcus  sp. or yeast. The third part of the composition is polyethylene glycol which may be administered simultaneously with the aforementioned fiber. Consumption of the fiber and aqueous solution combination plus probiotic and PEG by patients with constipation or Irritable Bowel Syndrome results in either a resolution of the symptoms or a marked improvement in symptoms without significant side effects. The disclosed combination and treatment method may be administered to patients with constipation and Irritable Bowel Syndrome for long periods of time without significant complications.
Hip extension exercise performed under inertial loading conditions using the EPTE Inertial Concept (Ionclinics SL, L'Alcudia, Spain) during six weeks with two sessions per week. The EPTE Inertial Concept is an inertial device that combines a series of output pulleys and telescopic arms, capable of implementing 6 disks of different weights and radii.
Squamous cell carcinoma is the culmination of a multistep carcinogenesis process that is preceded by early stages referred as squamous dysplasia and actinic keratosis. Squamous dysplasia (SD) also known as "field effect" is clinically characterized by xerosis (dry, scaly skin), lentigines and uneven pigmentation. While morphologically skin biopsies and cytology samples show only minimal changes, at the molecular level it is known that SD is characterized by small clone keratinocytes carrying mutations of the P53 gene. An optical technology called Partial Wave Spectroscopy (PWS) probes nanoscale structures in the order of tens to a few hundred nanometers. PWS is a light back-scattering techniques that uses light reflected off of a tissue sample. The measured biomarker is sensitive to the cytosolic and nucleic architecture within the cell and quantifies the nanoscale disorder, which conventional light microscopy fails to appreciate. PWS has allowed to identify various grades of structural disorder at the nanoscale level of colonic and pulmonary premalignant cell samples. Using PWS we aim to study the spectrum of cutaneous SD from patients at high risk for SCC development. Since squamous dysplasia is difficult to assess with routine histology and cytopathology and a grading system for squamous dysplasia by routine histology or cytology is not available, we propose to assess the value of PWS as a new and more sensitive imaging technique. By identifying the degree of SD at the molecular level, we may be able to intervene with close surveillance, early treatment and chemoprevention strategies to achieve lower morbidity by means of fewer and smaller skin cancers.
333369EPY2006 is the open-label extension study that follows the double-blind study 333369EPY2003. In an open label study such as 333369EPY2006, both the physician and the patient know the name of the assigned study medication. In a double blind study such as 333369EPY2003, neither the physician nor the patient knows the name of the assigned study medication. Patients who complete the double-blind treatment phase of study 333369EPY2003 will be eligible to enter the open-label extension study during which patients will transition through a blinded period to an open-label period with carisbamate (also referred to as RWJ-333369). RWJ-333369 is a new chemical compound with anticonvulsant activity that is currently under investigation as a treatment for epilepsy. Patients electing to enter the open-label extension phase will be supplied with both open-label carisbamate (RWJ-333369) and blinded study medication for the transition phase. During this transition phase (approximately 3 weeks in length), the patient's dose of double-blind study drug will be gradually reduced and stopped and treatment with open-label RWJ-333369 will be started. Throughout the remainder of the open label extension phase, investigators will be allowed to make further adjustments of the dosage and schedule of carisbamate, including independent adjustment of the morning and evening doses, but a dosage of 1,200 mg/day may not be exceeded and increases in dosage must be in increments of no more than 200 mg/day. After 12 months of participation in the open-label extension study, patients who, in the judgment of the investigator, continue to benefit from treatment with RWJ-333369 may continue to receive the drug with follow up clinic visits every 3 months until RWJ 333369 is available by prescription or the program is terminated by the sponsor. RWJ-333369 (100, 300, 800, or 1,600 milligrams per day) administered orally in 2 equally divided doses for up to 16 weeks of double-blind treatment followed by the option to continue RWJ-333369 treatment in an open-label study for at least 1 year, then until drug is available or production ceases.
PROBLEM TO BE SOLVED: To obtain a hair tonic which is utilized in fields of medicines, quasi- drugs and cosmetics and has excellent hair-restoring effect such as depiratory prevention and hair-growing effect by formulating an extract from plants of the family Menispermaceae and the family Nymphaeaceae. SOLUTION: This hair tonic is obtained by formulating at least one kind or more selected from extracts from plants of the family Menispermaceae, the genus Menispermum (e.g. Menispermum daurium DC.) or the genus Cocculus (e.g. Cocculus laurifolius DC., Cocculus trilobus DC., etc.), plants of the family Nymphaeaceae, the genus Nelumbo (e.g. Nelumbo nucifera Gaertn.), plants of the family Malvaceae, the genus Abelmoschus (e.g. Ahelmoschus crinitus, Ahelmoschus manihot, etc.), plants of the family Gnetaceae, the genus Gnetum (e.g. Gnetum montanum and the like) and plants of the family Lauraceae, the genus machilus (e.g. Machilus bracteate and the like) preferably in an amount of 0.005-10 wt.% based on the whole weight of the composition. This hair tonic can be prepared in dosage forms of liquid, emulsion and ointment.
The invention relates to the field of gene expression. The nucleotide sequence of a porcine alpha-interferon gene with efficient expression and high antiviral activity is shown as a sequence 2. Genes of the sequence 2 are cloned to a eukaryon expression vector to obtain a recombinant plasmid. A synthetic method of the porcine alpha-interferon gene comprises the following steps of: inserting a Rabbit beta-Globin Intron II, a pCMV immediate early promoter and a T7 promoter into pVAX1(C) to obtain pMVAX1(C); and inserting a maturation protein gene of pIFN-alpha into the pMVAX1(C) to obtain pMVAX1(C)-pIFN-alpha. The expression protein of the porcine alpha-interferon gene is applied to the preparation of a medicine for treating a porcine reproductive and respiratory syndrome. The porcine alpha-interferon gene with efficient expression and high antiviral activity breaks through the limitation that the expression amount is low and the activity is poor while being used for expressing the pIFN-alpha by the pMVAX1(C) carrier and the activity unit can be up to 2*10<7.0> U/0.1 mL; and through the porcine alpha-interferon gene provided by the invention, the proliferation of PRRSV (Porcine Reproductive and Respiratory Syndrome Viruses) with high pathogenicity can be obviously inhibited and the economic loss of a pig farm can be reduced.
OBJECTIVES: Metformin protects against age-related muscle decline, termed sarcopenia. However, the effects on sarcopenia quality-of-life (SarQoL) are unknown. We investigated the effects of metformin on SarQoL and associated mechanisms in older adults.
METHOD: This double-blind randomized, placebo-controlled trial included geriatric adult men, divided into non-sarcopenic controls (age = 72.2 ± 4.3 years, n = 52) and two groups of patients with sarcopenia randomized into placebo (age at baseline = 74.4 ± 5.7 years, n = 54) and metformin (age at baseline = 71.2 ± 3.9 years, n = 47) groups. Patients in the metformin group received 1.7 grams twice daily for four months. We evaluated SarQoL, handgrip strength (HGS), plasma zonulin, c-reactive protein (CRP), and 8-isoprostanes.
RESULTS: Patients with sarcopenia had lower HGS and SarQoL than controls (both p <0.05). Metformin improved the HGS and the SarQoL domains related to physical and mental health, locomotion, and leisure activities, as well as cumulative SarQoL scores (all p <0.05). Metformin also prevented the decline in the SarQoL domains for functionality and fear. Among plasma biomarkers, metformin reduced the levels of zonulin, CRP, 8-isoprostanes, and creatine kinase. We also found a significant correlation of plasma zonulin with cumulative SarQoL in patients with sarcopenia taking metformin, suggesting a role for intestinal repair in improving SarQoL. Finally, metformin did not affect body composition and gait speed.
CONCLUSION: Overall, metformin improved HGS and SarQoL by repairing intestinal leakage. Our data have clinical relevance for improving the quality of life in older adults with sarcopenia.
All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
Use of six specific compounds (A), and their hydrates, salts and hydrated salts, to prepare a composition for promoting healing of wounds. Use of six specific compounds (A), of formulae (I)-(VI), and their hydrates, salts and hydrated salts, to prepare a composition for promoting healing of wounds. An independent claim is also included for a pharmaceutical composition for promotion of wound healing that contains (A). [Image] [Image] [Image] ACTIVITY : Vulnerary; Antidiabetic. No biological data given. MECHANISM OF ACTION : Guanylate cyclase activators.
Pancreatic cancer is characterised by aggressive growth, treatment resistance and an extremely poor prognosis. In subjects with locally advanced or metastatic disease, the median survival is approximately 6 - 11 months and 2 - 6 months, respectively. The currently accepted treatment for this disease in EU is gemcitabine which supplanted treatment with 5-FU after it was shown that median survival duration was marginally improved (4.41 and 5.65 months respectively, p = 0,022). The reported median survival time for subjects treated with single-agent gemcitabine in randomized phase III studies ranged form 4.9 to 7.2 months. Despite these improvements in the treatment of pancreatic cancer, the prognosis remains very poor. Lenalidomide (Revlimid®) belongs to a proprietary class of compounds called immunomodulatory drugs (IMiDs). IMiDshave both immunomodulatory and anti-angiogenic properties which could confer antitumour and antimetastatic effects. Lenalidomide has been demonstrated to possess anti-angiogenic activity through inhibition of bFGF, VEGF and TNF-alpha induced endothelial cell migration, due at least in part to inhibition of Akt phosphorylation response to bFGF.In addition, lenalidomide has a variety of immunomodulatory effects. Gemcitabine (Gemzar®) is a synthetic pyrimidine nucleoside analogue that is used as standard treatment of advanced pancreatic cancer. Beside the cytotoxic activity of gemcitabine, accumulating evidence has indicated that the product promote specific anticancer immune responses that contribute to the therapeutic effects of conventional therapy.Down-regulation in survival rate of pancreatic cell lines has more recently been observed, when treated with lenalidomide and gemcitabine in sub-optimal concentrations.Those data supports a hypothesis of a potential hyper-additive affect of the treatments given in combination. Therefore lenalidomide and gemcitabine should be of major interest to explore for combination therapy.

This is a phase I/II open-label, multi-center study. It will consist of a phase I dose-finding part and a phase II part during which subjects will be treated at the MTD established during phase I. Lenalidomide will be administered by a stepwise dose-escalation schedule in the phase I part. Thus, the primary endpoint in the phase I part is to determine the MTD and safety of the regimen lenalidomide and gemcitabine as first-line treatment in subjects with advanced pancreatic cancer.In the phase II part, primary endpoint is to evaluate the immunomodulatory effects of lenalidomide in combination with gemcitabine in the same patient population.
The present invention relates to a purification method for antitumor medicament oxaliplatin. Oxaliplatin is dissolved in water of 40 to 90 DEG C, and then, potassium iodide is added to an oxaliplatin solution. The oxaliplatin solution is filtered, decompressed and concentrated after cooling and static placement, and an oxaliplatin product with a very low silver content is obtained. The concentration of the oxaliplatin solution is from 1 to 8 grams/liter. The silver content to potassium iodide in the oxaliplatin is 0.75: 1 to 8. The silver content of the oxaliplatin treated by the method is smaller than 5 ppm, an oxaliplatin content is greater than 99%, and a specific rotation is from 73 degrees to 78 degrees.
Use of chitosan for the preparation of a medication for the therapeutic treatment of leishmaniasis. The new use of chitosan for the preparation of a drug for the treatment of leishmaniasis is described. It is described that chitosan shows activity in vitro against promastigotes and intracellular amastigotes of leishmania. The chitosan can be used in the form of an acid solution or in the form of microparticles. Also disclosed are microparticles containing chitosan and another anti-leishmanial agent, such as meglumine antimonate. (Machine-translation by Google Translate, not legally binding)
Although research on the subject has only recently started developing, the links have already been described between SARS-Cov-2 infection, the severity of the clinical status, and the presence of risk factors or a history of cardiovascular disease (hypertension, diabetes, stroke, etc.). Additionally, depending on the series and definition used for cardiac injury (troponin elevation and/or natriuretic peptides), this concerns 7-29% of patients with a clear predominance in severe patients. The mechanisms behind these troponin elevations and cardiac injury are likely to be multiple and variable depending on clinical presentation,severity and patient history. A significant association was found between troponin elevation, and that of CRP and NtproBNP, suggesting an inflammatory part to this cardiac damage. As with other coronaviruses, SARS-Cov-2 infection can cause massive release of proinflammatory cytokines which can lead to inflammation of the vascular wall. This can be the cause of true instability or even rupture of plaque(type1 infarction) but can also be responsible for tissue hypoxia without rupture of plaque causing myocardial pain (infarction type 2). In addition, there may be areal myocardial inflammation causing acute myocarditis, secondary to the cytokine storm or direct damage to the myocardium by the virus itself. In case of acute coronary syndrome presentation, a coronary exploration should be realized to highlight or eliminate a type 1 infarction, but it is clearly difficult to distinguish between a type 2 suffering (no viral attack direct but suffering from hypotension or hypoxia for example) and inflammatory myocardial damage with or without direct viral myocardial damage (myocarditis). In the context of the viral pandemic at Covid19, although few data exist,it is legitimate to consider the possibility of true arrays of acute inflammatory myocarditis or by direct viral attack which could thus modify the natural history and the prognosis of patients, thus justifying a dedicated diagnosis and treatment. The primary objective was to assess the proportion of positive SARS-Cov-2 cases among the patients included (hospitalized for acute myocarditis). During the study period, this proportion will be assessed at regular intervals, for example every month, or more frequently if the number of patients included varies substantially from one week to another. This will make it possible to trace a development curve for the entire period of the pandemic.

The secondary objectives were (1) to describe the clinical, biological and imaging characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; (2) to assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort and (3) to identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis.
Allergic Reactions: Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine. However,  Lidotral™ 5% with Menthol Spray should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain. 

Non-intact Skin: Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of lidocaine from increased absorption.  Lidotral™ 5% with Menthol Spray is only recommended for use on intact skin. 

  
External Heat Sources: Placement of external heat sources, such as heating pads or electric blankets, over Lidotral™ 5% with Menthol Spray is not recommended as this has not been evaluated and may increase plasma lidocaine levels. 

Eye Exposure: The contact of Lidotral™ 5% with Menthol Spray with eyes, although not studied, should be avoided based on the findings of severe eye irritation with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.